A detailed history of Ghost Tree Capital, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Ghost Tree Capital, LLC holds 215,000 shares of IMVT stock, worth $5.91 Million. This represents 2.22% of its overall portfolio holdings.

Number of Shares
215,000
Previous 260,000 17.31%
Holding current value
$5.91 Million
Previous $6.86 Million 13.84%
% of portfolio
2.22%
Previous 2.8%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.51 - $27.51 $1.24 Million - $1.24 Million
-45,000 Reduced 17.31%
215,000 $5.91 Million
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $3.39 Million - $4.27 Million
135,000 Added 108.0%
260,000 $6.86 Million
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $3.78 Million - $5.47 Million
125,000 New
125,000 $4.04 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $2.41 Million - $5.19 Million
130,000 New
130,000 $4.99 Million
Q1 2021

May 14, 2021

SELL
$13.08 - $49.6 $654,000 - $2.48 Million
-50,000 Reduced 16.67%
250,000 $4.01 Million
Q4 2020

Feb 16, 2021

SELL
$36.36 - $52.71 $8.18 Million - $11.9 Million
-225,000 Reduced 42.86%
300,000 $13.9 Million
Q2 2020

Aug 14, 2020

SELL
$13.87 - $28.44 $2.57 Million - $5.26 Million
-185,000 Reduced 26.06%
525,000 $12.8 Million
Q1 2020

May 15, 2020

SELL
$8.36 - $17.13 $752,400 - $1.54 Million
-90,000 Reduced 11.25%
710,000 $11.1 Million
Q4 2019

Feb 14, 2020

BUY
$10.02 - $16.4 $8.02 Million - $13.1 Million
800,000 New
800,000 $12.7 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Ghost Tree Capital, LLC Portfolio

Follow Ghost Tree Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ghost Tree Capital, LLC with notifications on news.